# EDGAR Filing Document

**Accession Number:** 0001386570
**File Stem:** 0001386570-26-000023
**Filing Date:** 2026-4
**Character Count:** 6740
**Document Hash:** e8e31edf12f69b21cf179f38724fb9c0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001386570-26-000023.hdr.sgml**: 20260429

**ACCESSION NUMBER**: 0001386570-26-000023

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260429

**DATE AS OF CHANGE**: 20260429

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Niagen Bioscience, Inc.
- **CENTRAL INDEX KEY:** 0001386570
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 262940963
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37752
- **FILM NUMBER:** 26915840

**BUSINESS ADDRESS:**
- **STREET 1:** 10900 WILSHIRE BLVD
- **STREET 2:** SUITE 600
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90024
- **BUSINESS PHONE:** 310-388-6706

**MAIL ADDRESS:**
- **STREET 1:** 10900 WILSHIRE BLVD
- **STREET 2:** SUITE 600
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90024

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ChromaDex Corp.
- **DATE OF NAME CHANGE:** 20080624

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CODY RESOURCES, INC.
- **DATE OF NAME CHANGE:** 20070112

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A**

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant ☑

Filed by a party other than the Registrant ☐

---

| | |
|:---|:---|
| Check the appropriate box: | Check the appropriate box: |
| ☐ | Preliminary Proxy Statement |
| ☐ | **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))** |
| ☐ | Definitive Proxy Statement |
| ☑ | Definitive Additional Materials |
| ☐ | Soliciting Material under §240.14a-12 |
| **NIAGEN BIOSCIENCE, INC.** | **NIAGEN BIOSCIENCE, INC.** |
| **(Name of Registrant as Specified In Its Charter)** | **(Name of Registrant as Specified In Its Charter)** |
| **(Name of Person(s) Filing Proxy Statement, if other than the Registrant)** | **(Name of Person(s) Filing Proxy Statement, if other than the Registrant)** |
| Payment of Filing Fee (Check all boxes that apply): | Payment of Filing Fee (Check all boxes that apply): |
| ☑ | No fee required. |
| ☐ | Fee paid previously with preliminary materials |
| ☐ | Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |

---

![](niagenbioscience_notice001.jpg)

www.investorvote.com/NAGE Step 1: Go to www.investorvote.com/NAGE. Step 2: Click on the icon on the right to view meeting materials. Step 3: Return to the investorvote.com window and follow the instructions on the screen to log in. Online Go to www.investorvote.com/NAGE or scan the QR code — login details are located in the shaded bar below. Shareholder Meeting Notice 049TYA Important Notice Regarding the Availability of Proxy Materials for the Niagen Bioscience, Inc. Annual Shareholder Meeting to be Held on June 24, 2026 Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual shareholders' meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The 2025 Annual Report and Proxy Statement are available at www.Niagenbioscience.com, Investor Relations Section and: Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before June 14, 2026 to facilitate timely delivery. 2 N O T Easy Online Access — View your proxy materials and vote. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares. Votes submitted electronically must be received by 11:59 pm, ET on June 23, 2026. MMMMMMMMMMMM M M M M M M M M M 0 0 0 0 0 1 MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 ADD 5 ADD 6 ENDORSEMENT_LINE______________ SACKPACK_____________ 1234 5678 9012 345 C 1234567890 C O Y MMMMMMM

------

![](niagenbioscience_notice002.jpg)

Here's how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.investorvote.com/NAGE. — Phone – Call us free of charge at 1-866-641-4276. — Email – Send an email to investorvote@computershare.com with "Proxy Materials Niagen Bioscience, Inc." in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by June 14, 2026. Niagen Bioscience, Inc.'s Annual Meeting of Shareholders will be held on Wednesday, June 24, 2026 at 3:00 pm PT. The meeting will be held at 10900 Wilshire Blvd. Suite 600, Los Angeles, CA 90024. Proposals to be voted on at the meeting are listed below along with the Board of Directors' recommendations. The Board of Directors recommend a vote FOR all the nominees listed and FOR Proposals 2 and 3. 1. Election of Directors: 01 - Frank Jaksch, Jr. 02 - Robert Fried 03 - Steven Rubin 04 - Wendy Yu 05 - Gary Ng 06 - Kristin Patrick 07 - Ann Cohen 08 - Hamed Shahbazi 2. Ratification of the Audit Committee's selection of Crowe LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 3. A nonbinding advisory vote of the Company's stockholders, as recommended by the Compensation Committee and approved by the Board, on the compensation of the Company's named executive officers disclosed in the Proxy Solicitation Materials PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. Shareholder Meeting Notice

------